LLY

901.29

-0.96%↓

JNJ

235.03

-0.28%↓

ABBV

204.68

-0.16%↓

NVS

148.56

+0.66%↑

AZN

185.31

+0.58%↑

LLY

901.29

-0.96%↓

JNJ

235.03

-0.28%↓

ABBV

204.68

-0.16%↓

NVS

148.56

+0.66%↑

AZN

185.31

+0.58%↑

LLY

901.29

-0.96%↓

JNJ

235.03

-0.28%↓

ABBV

204.68

-0.16%↓

NVS

148.56

+0.66%↑

AZN

185.31

+0.58%↑

LLY

901.29

-0.96%↓

JNJ

235.03

-0.28%↓

ABBV

204.68

-0.16%↓

NVS

148.56

+0.66%↑

AZN

185.31

+0.58%↑

LLY

901.29

-0.96%↓

JNJ

235.03

-0.28%↓

ABBV

204.68

-0.16%↓

NVS

148.56

+0.66%↑

AZN

185.31

+0.58%↑

Search

Charles River Laboratories International Inc

Fechado

SetorSaúde

159.46 1.38

Visão Geral

Variação de preço das ações

24h

Atual

Mín

153.24

Máximo

160.97

Indicadores-chave

By Trading Economics

Rendimento

-332M

-277M

Vendas

-11M

994M

EPS

2.43

Margem de lucro

-27.816

Funcionários

18,300

EBITDA

730K

198M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+30.31% upside

Dividendos

By Dow Jones

Próximos Ganhos

6 de mai. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-163M

7.8B

Abertura anterior

158.08

Fecho anterior

159.46

Sentimento de Notícias

By Acuity

100%

0%

333 / 350 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Strong Bullish Evidence

Charles River Laboratories International Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

24 de mar. de 2026, 18:58 UTC

Grandes Movimentos do Mercado

MDA Space Shares Drop After NASA Shifts Focus to Moon's Surface and Away From Space Station

24 de mar. de 2026, 23:48 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

24 de mar. de 2026, 23:48 UTC

Conversa de Mercado

Nikkei May Rise on Hopes for U.S.-Iran Talks -- Market Talk

24 de mar. de 2026, 23:33 UTC

Conversa de Mercado
Notícias Principais

Gold Rises, Boosted by Dollar Weakness -- Market Talk

24 de mar. de 2026, 23:16 UTC

Conversa de Mercado

Venezuelan Opposition Leader Says Oil Output Could Reach 5 Million B/D -- Market Talk

24 de mar. de 2026, 22:40 UTC

Ganhos

Shanghai Fosun Pharmaceutical: Results Supported by Higher Rev From Innovative Drugs, Overseas Business >2196.HK

24 de mar. de 2026, 22:40 UTC

Ganhos

Shanghai Fosun Pharmaceutical 2025 Net CNY3.37B Vs. Net CNY2.77B >2196.HK

24 de mar. de 2026, 22:40 UTC

Ganhos

Shanghai Fosun Pharmaceutical 2025 Rev CNY41.50B Vs. CNY40.91B >2196.HK

24 de mar. de 2026, 21:44 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

24 de mar. de 2026, 21:44 UTC

Conversa de Mercado

Sandfire's New Bull Excited by Kalkaroo Copper Deposit -- Market Talk

24 de mar. de 2026, 20:59 UTC

Ganhos

Medtronic PLC Cuts FY26 View To Adj EPS $5.50-Adj EPS $5.54 >MDT

24 de mar. de 2026, 20:58 UTC

Notícias Principais

Israel Hits Russian-Iranian Weapons Smuggling Route in the Caspian Sea -- WSJ

24 de mar. de 2026, 20:50 UTC

Conversa de Mercado
Notícias Principais

Energy & Utilities Roundup: Market Talk

24 de mar. de 2026, 20:50 UTC

Conversa de Mercado
Notícias Principais

Basic Materials Roundup: Market Talk

24 de mar. de 2026, 20:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

24 de mar. de 2026, 20:25 UTC

Ganhos

This Palantir-Linked Drone Stock Was Flying Under the Radar -- Until Now -- Barrons.com

24 de mar. de 2026, 20:15 UTC

Conversa de Mercado
Notícias Principais

Global Commodities Roundup: Market Talk

24 de mar. de 2026, 20:10 UTC

Conversa de Mercado

Canada Mortgage Arrears Linked to Labor Market Performance -- Market Talk

24 de mar. de 2026, 20:10 UTC

Ganhos

Worthington Enterprises 3Q Sales $378.7M >WOR

24 de mar. de 2026, 20:10 UTC

Ganhos

Worthington Enterprises 3Q Adj EPS 98c >WOR

24 de mar. de 2026, 20:10 UTC

Ganhos

Worthington Enterprises 3Q EPS 92c >WOR

24 de mar. de 2026, 19:25 UTC

Conversa de Mercado
Notícias Principais

Canada Needs Roughly 100 Days to Meet IEA's Oil-Stock Release -- Market Talk

24 de mar. de 2026, 19:06 UTC

Conversa de Mercado
Notícias Principais

Oil Futures Regain Ground As Strikes Continue in Middle East -- Market Talk

24 de mar. de 2026, 18:51 UTC

Conversa de Mercado
Notícias Principais

U.S. Natural Gas Settles Higher As Oil Futures Gain -- Market Talk

24 de mar. de 2026, 18:40 UTC

Conversa de Mercado
Notícias Principais

Global Forex and Fixed Income Roundup: Market Talk

24 de mar. de 2026, 18:40 UTC

Conversa de Mercado
Notícias Principais

Mideast Conflict to Hobble But Not Derail Canadian Economy -- Market Talk

24 de mar. de 2026, 18:34 UTC

Notícias Principais

Oil Production in the Middle East Will Take Months to Come Back, CEO says. Why $100 Oil Could Be Here to Stay. -- Barrons.com

24 de mar. de 2026, 18:27 UTC

Conversa de Mercado

Inflation Pickup Could Keep Bank of Mexico on Hold -- Market Talk

24 de mar. de 2026, 18:21 UTC

Conversa de Mercado
Notícias Principais

Silver Snaps 9-Session Losing Streak -- Market Talk

24 de mar. de 2026, 18:00 UTC

Aquisições, Fusões, Aquisições de Empresas

Gilead to Buy Ouro Medicines for $2.2 Billion. Why the Deal Is Key to Future Stock Gains. -- Barrons.com

Comparação entre Pares

Variação de preço

Charles River Laboratories International Inc Previsão

Preço-alvo

By TipRanks

30.31% parte superior

Previsão para 12 meses

Média 205.89 USD  30.31%

Máximo 265 USD

Mínimo 175 USD

Com base em 11 analistas de Wall Street que oferecem metas de preço de 12 meses para Charles River Laboratories International Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

11 ratings

8

Comprar

3

Manter

0

Vender

Pontuação Técnica

By Trading Central

117.16 / 144.77Suporte e Resistência

Curto Prazo

Strong Bullish Evidence

Médio Prazo

Weak Bullish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

333 / 350 Ranking em Saúde

Sentimento de Notícias

Evidência Muito Forte de Tendência de Baixa

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat